Posted on 6월 9, 20206/9/20
What Canada’s IRP Changes Could Mean for the Industry
Posted on 4월 29, 20204/29/20
Clinical Pathways and Policy to Guard Against Misaligned Incentives
Posted on 4월 15, 20204/15/20
What kind of clinical data is required for FDA clearance of a Digital Medicine?
Posted on 4월 10, 20204/10/20
What specifically triggers FDA regulation of a digital medicine?
Posted on 3월 9, 20203/9/20
Evolving Processes to Manage Value-Based Contracts
Posted on 3월 3, 20203/3/20
Realizing Value from Digital in the Healthcare Environment [Slides]
Posted on 12월 23, 201912/23/19
ICER’s Unsupported Price Increase Assessment
Posted on 11월 30, 201911/30/19
What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.
Posted on 11월 21, 201911/21/19
Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review
Posted on 10월 23, 201910/23/19